PRESS RELEASE:

Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy

| From
targeted genetic medicines

SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled "Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer" (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA. What the reader will gain: In recording the development of Rexin-G as a novel targeted biological therapy, this review also highlights important aspects of vector engineering which served to overcome the physiological barriers to gene delivery as it addresses the key regulatory issues involved in the development of a targeted gene therapy product. Take home message: Progressive clinical development of Rexin-G demonstrates the potential safety and efficacy of targeted genetic medicine in otherwise intractable cancers, while validating the design engineering of the molecular biotechnology platform.

The second article, entitled "Noteworthy Clinical Case Studies in Cancer Gene Therapy" (Intl. J. Oncology, April, 2010) highlights important aspects of Rexin-G bio-pharmacology, as this tumor-targeted vector advances as an efficacious anti-cancer agent. What the reader will gain: These remarkable case studies, in and of themselves, reveal important aspects of the molecular pharmacology, advanced clinical protocols, refinement of patient monitoring, expanding treatment options, and strategic medical approaches to patient care that exemplify and thereby extend the established principles of pathotropic targeting and cancer gene therapy to a new generation of clinical practitioners. Take home message: Each case study, in an otherwise intractable cancer, "teaches" a vital lesson in the emerging praxis of cancer control.

Finally, the third article comes in the form of a Mini review entitled "Nanoparticles and the Immune System" (Endocrinology, Feb, 2010) co-authored by members of the FDA Center for Drug Evaluation and Research, Office of Pharmaceutical Science, and the Nanotechnology Characterization Laboratory of the National Cancer Institute. What the reader will gain: This astute review of medical nanotechnology aptly describes the concept of targeted delivery of Rexin-G followed by Reximmune-C as a two-tier complementary approach aimed at both tumor eradication and personalized cancer vaccination. That is, the first step involves the use of Rexin-G to target and control the progression of metastatic cancer, whereas the second step employs Reximmune-C to induce a localized cancer immunization. Take home message: This is a commendable and timely review of these first-in-class, best-in-class tumor-targeted anti-cancer agents, which may supersede more cumbersome approaches to personalized cancer vaccinations.

About Epeius Biotechnologies:

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems. To learn more about our recent publications and/or proprietary biotechnologies, please visit www.epeiusbiotech.com .

News Source:
Like, Share, Save this press release:
  TWEET   SHARE   G+   PIN IT   STUMBLE   LinkedIn   Instapaper   Buffer

PERMALINK:
https://www.send2press.com/newswire/2010-05-0504-001.shtml
  LEGAL NOTICE AND TERMS OF USE:  
The content of the above press release was provided by the “news source” (Epeius Biotechnologies Corporation) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2010 Epeius Biotechnologies Corporation with newswire version Copr. © 2010 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Sep 26 2016:
[ count retired 8.4.16 ]


back to top
REFERENCES: targeted genetic medicines, Metastatic Cancer Research, Epeius Biotechnologies Corporation, targeted genetic medicine, Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer, (Expert Opinion on Biological Therapy, Erlinda M Gordon MD, biopharmaceutical company, oncology products, California company, Nanoparticles and the Immune System, biotech, news, press release from Epeius Biotechnologies Corporation, May 4, 2010, Drugs and Pharmaceuticals, Medical, , San Marino, California, Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy